Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 74,380 | 71,539 | 60,119 | 60,099 | 54,268 |
| Cost of Goods | 10,996 | 11,898 | 8,728 | 9,478 | 13,593 |
| Gross Profit | 63,384 | 59,641 | 51,391 | 50,621 | 40,675 |
| Operating Expenses | 57,649 | 56,057 | 55,209 | 49,420 | 54,161 |
| Operating Income | 6,731 | 4,482 | -3,090 | 1,679 | -12,893 |
| Interest Expense | 7,268 | 7,358 | 7,305 | 7,703 | 7,786 |
| Other Income | 1,158 | 948 | 1,175 | 911 | 1,617 |
| Pre-tax Income | 621 | -1,928 | -9,220 | -5,113 | -19,062 |
| Income Tax | N/A | N/A | N/A | 0 | -3,324 |
| Net Income Continuous | 621 | -1,928 | -9,220 | -5,113 | -15,738 |
| Net Income | $621 | $-1,928 | $-9,220 | $-5,113 | $-15,738 |
| EPS Basic Total Ops | 0.00 | -0.01 | -0.06 | -0.02 | -0.11 |
| EPS Basic Continuous Ops | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 |
| EPS Diluted Total Ops | 0.00 | -0.01 | -0.06 | -0.02 | -0.11 |
| EPS Diluted Continuous Ops | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 |
| EPS Diluted Before Non-Recurring Items | 0.00 | -0.01 | -0.06 | -0.03 | -0.06 |
| EBITDA(a) | $10,763 | $8,466 | $897 | $5,636 | $-8,484 |